2023 World Conference on Lung Cancer (Posters)-EP07.04. Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center

EP07.04. Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center - PDF(Slides)

Back to course

Pdf Summary

This study aimed to examine the outcomes of surgical resection in patients with early-stage EGFR mutated non-small cell lung cancer (NSCLC) at a large academic medical center. The researchers utilized the Northwestern Medicine OncoSET Molecular Database to identify patients who met inclusion criteria, including a new diagnosis of resected EGFR-mutated NSCLC and an EGFR mutation sensitive to osimertinib.<br /><br />In total, 58 patients were included in the study. Information regarding stage, resection type, mutations, and receipt of chemotherapy or targeted therapy was obtained. At a median follow-up of 13.1 months, none of the patients had experienced disease recurrence. This suggests a favorable prognosis for patients with early-stage EGFR mutated NSCLC who undergo surgical resection.<br /><br />The demographic and molecular characteristics of the patients were also analyzed. The majority of the patients were female (72.4%) and white/Caucasian (69.0%). The most common EGFR mutation was exon 19 deletion (44.8%), followed by exon 21 (L858R) mutation (53.5%). The majority of patients underwent sublobar resection (62.1%) rather than lobectomy (37.9%).<br /><br />In terms of treatment, a small percentage of patients received adjuvant chemotherapy (13.8%) or neoadjuvant chemotherapy (1.7%). A larger proportion of patients received adjuvant osimertinib (40.0%) after chemotherapy.<br /><br />The study also revealed that most patients would not have met the criteria for lung cancer screening recommended by the US Preventive Services Task Force (USPSTF).<br /><br />Overall, this study demonstrates that surgical resection in patients with early-stage EGFR mutated NSCLC can lead to favorable outcomes, with no disease recurrence observed at the median follow-up of 13.1 months. Further research is needed to validate these findings and determine the long-term outcomes of these patients.

Asset Subtitle

Joseph Fuchs

Meta Tag

Speaker Joseph Fuchs

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

surgical resection

EGFR mutated non-small cell lung cancer

NSCLC

academic medical center

Northwestern Medicine OncoSET Molecular Database

osimertinib

disease recurrence

demographic characteristics

molecular characteristics

adjuvant chemotherapy